
1. acs med chem lett. 2013 may 17;4(7):606-11. doi: 10.1021/ml400009t. ecollection
2013 jul 11.

4-substituted 2-hydroxyisoquinoline-1,3(2h,4h)-diones novel class hiv-1
integrase inhibitors.

billamboz m(1), suchaud v(1), bailly f(1), lion c(1), demeulemeester j(2),
calmels c(3), andréola ml(3), christ f(2), debyser z(2), cotelle p(1).

author information: 
(1)université lille nord de france , f-59000 lille, france ; université lille 1
sciences & technologies , ea 4478 chimie moléculaire et formulation, f-59655
villeneuve d'ascq, france.
(2)ku leuven , molecular virology gene therapy (vctb+5), kapucijnenvoer 33,
b-3000 leuven, flanders, belgium.
(3)umr 5234 cnrs, université bordeaux segalen , 146 rue léo saignat, f-33076
bordeaux, france.

a series 2-hydroxy-1,3-dioxoisoquinoline-4-carboxamides featuring an
n-hydroxyimide chelating functionality evaluated inhibitory
properties human immunodeficiency virus type 1 integrase (hiv-1 in).
several derivatives displayed low nanomolar ic50 values comparable the
clinically used raltegravir. marked effect one compound primary
in-catalyzed reactions, strand transfer (st), 3' processing (3'-p),
emphasizes novel inhibition mechanism establishing potential new
generation inhibitor. substitution 2-hydroxyisoquinoline-1,3-dione
scaffold position 4 carboxamido chains beneficial antiviral
activity since reproducible low micromolar anti-hiv activities obtained 
the first time within scaffold.

doi: 10.1021/ml400009t 
pmcid: pmc4027527
pmid: 24900718 

